abstract |
A method is provided for treating a patient in need of therapy for central nervous system inflammation comprising administering to that patient a therapeutically effective amount of a cannabinoid agonist having efficacy at the CB 2 receptor but having substantially no efficacy at the CB 1 receptor at that amount. |